The NHS Alliance is broadly supportive of the PPRS negotiations. These negotiations have always generated greater value from branded medicines to the NHS and money that can be further invested in front line services. We welcome the recognition of NICE in establishing the cost effectiveness of technologies and its greater role in value based assessments and pricing. The NHS Alliance hopes that all of the savings resultant from the PPRS agreement can be reinvested back into front line services and the increased uptake of innovative medicines through the appropriate commissioner.
Mark Robinson, NHS Alliance Pharmacy Lead said: “We believe that the PPRS provides an ideal opportunity to create savings in branded medicines that could be passed back to front line commissioners to be reinvested in those innovate medicines and treatment pathways to benefit patients.”
